Principal Securities Inc. Purchases 409 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Principal Securities Inc. lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 23.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,133 shares of the medical equipment provider’s stock after purchasing an additional 409 shares during the quarter. Principal Securities Inc.’s holdings in Zimmer Biomet were worth $225,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC raised its stake in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet during the third quarter valued at $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet during the third quarter valued at $35,000. Finally, Kentucky Trust Co purchased a new position in Zimmer Biomet during the fourth quarter valued at $39,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.2 %

Zimmer Biomet stock opened at $104.89 on Monday. The stock has a market cap of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The stock has a fifty day moving average of $105.86 and a 200 day moving average of $107.46.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm earned $2.20 earnings per share. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Stifel Nicolaus lifted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Wells Fargo & Company lifted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial reiterated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Finally, Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.